BAX Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of -1.8% compared to Baxter International, Inc.'s net margin of 14.91%. Baxter International, Inc.'s return on equity of -4.83% beat Boston Scientific Corp.'s return on equity of 12.46%.

Baxter International, Inc. has a consensus price target of $23.13, signalling upside risk potential of 15.26%. On the other hand Boston Scientific Corp. has an analysts' consensus of $124.41 which suggests that it could grow by 33.01%. Given that Boston Scientific Corp. has higher upside potential than Baxter International, Inc., analysts believe Boston Scientific Corp. is more attractive than Baxter International, Inc..

Baxter International, Inc. has a beta of 0.594, which suggesting that the stock is 40.626% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.59%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Baxter International, Inc. quarterly revenues are $2.8B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Baxter International, Inc.'s net income of -$51M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while Boston Scientific Corp.'s PE ratio is 50.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.93x versus 7.22x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Holdings, Inc. has a net margin of -1.8% compared to Baxter International, Inc.'s net margin of -2.7%. Baxter International, Inc.'s return on equity of -4.83% beat iRhythm Holdings, Inc.'s return on equity of -54.18%.

Baxter International, Inc. has a consensus price target of $23.13, signalling upside risk potential of 15.26%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $220.60 which suggests that it could grow by 42.77%. Given that iRhythm Holdings, Inc. has higher upside potential than Baxter International, Inc., analysts believe iRhythm Holdings, Inc. is more attractive than Baxter International, Inc..

Baxter International, Inc. has a beta of 0.594, which suggesting that the stock is 40.626% less volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.075%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.59%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.

Baxter International, Inc. quarterly revenues are $2.8B, which are larger than iRhythm Holdings, Inc. quarterly revenues of $192.9M. Baxter International, Inc.'s net income of -$51M is lower than iRhythm Holdings, Inc.'s net income of -$5.2M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.93x versus 6.99x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of -1.8% compared to Baxter International, Inc.'s net margin of 27.89%. Baxter International, Inc.'s return on equity of -4.83% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Baxter International, Inc. has a consensus price target of $23.13, signalling upside risk potential of 15.26%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 21.34%. Given that Intuitive Surgical, Inc. has higher upside potential than Baxter International, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than Baxter International, Inc..

Baxter International, Inc. has a beta of 0.594, which suggesting that the stock is 40.626% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.59%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Baxter International, Inc. quarterly revenues are $2.8B, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Baxter International, Inc.'s net income of -$51M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while Intuitive Surgical, Inc.'s PE ratio is 63.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.93x versus 18.17x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of -1.8% compared to Baxter International, Inc.'s net margin of -8.49%. Baxter International, Inc.'s return on equity of -4.83% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.

Baxter International, Inc. has a consensus price target of $23.13, signalling upside risk potential of 15.26%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $25.95 which suggests that it could grow by 30.48%. Given that Tandem Diabetes Care, Inc. has higher upside potential than Baxter International, Inc., analysts believe Tandem Diabetes Care, Inc. is more attractive than Baxter International, Inc..

Baxter International, Inc. has a beta of 0.594, which suggesting that the stock is 40.626% less volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.218%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.59%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.

Baxter International, Inc. quarterly revenues are $2.8B, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Baxter International, Inc.'s net income of -$51M is lower than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.93x versus 1.32x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.